Many people around the world use proton pump inhibitors (PPIs) for conditions like heartburn, gastritis, and stomach ulcers.
A recent study in the journal Alzheimer’s & Dementia found that the long-term use of these drugs could increase the risk of developing dementia.
Researchers found that PPIs affect the synthesis of the neurotransmitter acetylcholine, which plays a significant part in conditions such as Alzheimer’s disease.
Previous studies have previously shown higher rates of dementia in people using PPIs, but the connection was unclear until now.
In the study, the researchers used 3-D computer simulations to examine how six PPI variants based on different active substances interacted with an enzyme called choline acetyletransferase, the function of which is to synthesize the neurotransmitter acetylcholine.
As a neurotransmitter, acetylcholine is needed for passing signals among nerve cells, but this only works if enough of the substance is produced. The analysis showed that all the tested drugs were able to bind with the enzyme.
The researchers then analyzed the effect of this binding. They found that all the drugs inhibited the enzyme, resulting in reduced production of acetylcholine, where the stronger the binding, the stronger the inhibitory effect.
Drugs based on the active substances omeprazole, esomeprazole, tenatoprazole, and rabeprazole had the greatest affinity and were, therefore, the strongest inhibitors of the enzyme, while the variants pantoprazole and lansoprazole were the weakest (see illustration).
Complementary studies are now needed to examine whether these laboratory observations represent what occurs in the body.
However, the team is already advising against the overuse of PPIs.
They say special care should be taken with the more elderly patients and those already diagnosed with dementia.
The same also applies to patients with muscle weakness diseases such as ALS, as acetylcholine is an essential motor neurotransmitter.
In such cases, doctors should use the drugs that have the weakest effect and prescribe them at the lowest dose and for as short a time as possible.
If you care about Alzheimer’s and dementia, please read studies about the main cause of dementia and findings of a new risk factor for Alzheimer’s and related dementias.
For more information about Alzheimer’s and your health, please see recent studies about a new culprit of cognitive decline in Alzheimer’s and results showing that this drug may protect you from Alzheimer’s if used early.
The study is from Karolinska Institutet in Sweden. One author is Taher Darreh-Shori.
Copyright © 2021 Knowridge Science Report. All rights reserved.